Device Trial Radar · NCT03297125
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 1, 2017
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Medical College of WisconsinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 29, 2017
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Conditions
- Glioblastoma
Interventions
Standard Magnetic Resonance Imaging (MRI)Device
Standard MRI.
Advanced MRI.Device
Perfusion and diffusion MRI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival.Time frame: Six months.
- Overall survival.Time frame: One year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.